Denali Therapeutics Inc.

DB:4DN Stock Report

Market Cap: €3.1b

Denali Therapeutics Management

Management criteria checks 3/4

Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 10.92 years. total yearly compensation is $4.75M, comprised of 15.1% salary and 84.9% bonuses, including company stock and options. directly owns 1.43% of the company’s shares, worth €44.75M. The average tenure of the management team and the board of directors is 7.5 years and 7.3 years respectively.

Key information

Ryan Watts

Chief executive officer

US$4.8m

Total compensation

CEO salary percentage15.11%
CEO tenure10.9yrs
CEO ownership1.4%
Management average tenure7.5yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ryan Watts's remuneration changed compared to Denali Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$508m

Dec 31 2025US$5mUS$718k

-US$513m

Sep 30 2025n/an/a

-US$499m

Jun 30 2025n/an/a

-US$479m

Mar 31 2025n/an/a

-US$454m

Dec 31 2024US$7mUS$690k

-US$423m

Sep 30 2024n/an/a

-US$427m

Jun 30 2024n/an/a

-US$420m

Mar 31 2024n/an/a

-US$137m

Dec 31 2023US$8mUS$670k

-US$145m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$371m

Dec 31 2022US$9mUS$645k

-US$326m

Sep 30 2022n/an/a

-US$303m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$13mUS$610k

-US$291m

Sep 30 2021n/an/a

US$30m

Jun 30 2021n/an/a

US$56m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$9mUS$589k

US$71m

Sep 30 2020n/an/a

-US$228m

Jun 30 2020n/an/a

-US$216m

Mar 31 2020n/an/a

-US$215m

Dec 31 2019US$5mUS$567k

-US$198m

Compensation vs Market: Ryan's total compensation ($USD4.75M) is above average for companies of similar size in the German market ($USD2.19M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.

CEO

Ryan Watts (50 yo)

10.9yrs
Tenure
US$4,751,515
Compensation

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...

Leadership Team

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder10.9yrsUS$4.75m1.43%
€ 44.7m
Alexander Schuth
Co-Founder11.3yrsUS$4.26m0.42%
€ 13.1m
Dana Andersen
Chief Technical and Manufacturing Officer7.9yrsno datano data
Joe Lewcock
Chief Scientific Officer6yrsno datano data
Chris Walsh
General Counsel7.5yrsno datano data
Cindy Dunkle
Chief People Officerno datano datano data
Katie Peng
Chief Commercial Officer4.8yrsno datano data
Peter Chin
Acting Chief Medical Officer & Head of Developmentless than a yearno data0.13%
€ 4.0m
7.5yrs
Average Tenure
54yo
Average Age

Experienced Management: 4DN's management team is seasoned and experienced (7.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder11.3yrsUS$4.75m1.43%
€ 44.7m
Jay Flatley
Independent Director11.3yrsUS$316.38k0.22%
€ 7.0m
Julian Baker
Independent Chairperson1.1yrsUS$474.35k0.21%
€ 6.6m
Eric Reiman
Member of Scientific Advisory Boardno datano datano data
David Schenkein
Independent Director11.3yrsUS$311.38k0.046%
€ 1.4m
David Holtzman
Member of Scientific Advisory Board5.7yrsno datano data
Peter Klein
Independent Director8.3yrsUS$318.88k0.017%
€ 544.1k
Jennifer Cook
Independent Director7.7yrsUS$301.38k0.016%
€ 515.3k
Steve Krognes
Independent Director4.2yrsUS$297.15k0.51%
€ 16.1m
Stacie Weninger
Member of Scientific Advisory Board5.5yrsno datano data
Henrik Zetterberg
Member of Scientific Advisory Board7.3yrsno datano data
Nancy Thornberry
Independent Director5.5yrsUS$306.38k0.016%
€ 488.3k
7.3yrs
Average Tenure
62yo
Average Age

Experienced Board: 4DN's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/15 14:58
End of Day Share Price 2026/07/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Denali Therapeutics Inc. is covered by 33 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Joel BeattyBaird
Charles MooreBaird